Latest News

Are trial data generalizable to MS population?


An analysis of patients in the German MS Register has found that 83% of real-world patients would not have met inclusion/exclusion criteria for entry in a trial of disease-modifying therapies (Jalusic et al. Mult Scler 2021; epublished January 20, 2021). Read More